Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Indivior Pharmaceuticals (INDV) EBITDA Margin (2022 - 2026)

Indivior Pharmaceuticals has reported EBITDA Margin over the past 5 years, most recently at 43.22% for Q1 2026.

  • For Q1 2026, EBITDA Margin rose 2480.0% year-over-year to 43.22%; the TTM value through Mar 2026 reached 21.77%, up 1895.0%, while the annual FY2025 figure was 21.15%, 2308.0% up from the prior year.
  • EBITDA Margin for Q1 2026 was 43.22% at Indivior Pharmaceuticals, up from 22.63% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 43.22% in Q1 2026 and troughed at 107.05% in Q4 2022.
  • A 5-year average of 3.93% and a median of 19.45% in 2023 define the central range for EBITDA Margin.
  • On a YoY basis, EBITDA Margin climbed as much as 12753bps in 2023 and fell as far as -9167bps in 2023.
  • Year by year, EBITDA Margin stood at 107.05% in 2022, then soared by 119bps to 20.48% in 2023, then fell by -25bps to 15.44% in 2024, then skyrocketed by 47bps to 22.63% in 2025, then skyrocketed by 91bps to 43.22% in 2026.
  • Business Quant data shows EBITDA Margin for INDV at 43.22% in Q1 2026, 22.63% in Q4 2025, and 13.69% in Q3 2025.